राजस्थान सरकार
निदेशालय, चिकित्सा एवं स्वास्थ्य सेवायें, राजस्थान, जयपुर

प्रमाण: आई.डी.एस.पी./2020/721

प्रधानमंत्री एवं नियंत्रक,
एस.एम.एस., मेडिकल कॉलेज,
जयपुर, राजस्थान।

विषय:— आयुर्वेद विभाग द्वारा कोविड–19 हेतु कोरोना रोगियों पर आंशिक परीक्षण पर विशेष टिप्पणी बाबत्।

उपरोक्त विषयान्तरगत राष्ट्रीय आयुर्वेद संस्थान के कोविड–19 के संदिग्धों व कोरोना पॉजिटिव रोगियों पर आंशिक परीक्षण/उपयोगिता की स्वीकृति से संबंधित प्राप्त प्रस्ताव (संलग्न पताका अ) सलाम छात्र लेख है कि उक्त प्रस्ताव पर एसएमएस, मेडिकल कॉलेज, जयपुर में गठित Ethics Committee एवं Clinical Trial Screeing Committee से विशेष टिप्पणी लिये जाने का श्रम कराये।

उक्त पत्र सक्षम स्तर से अनुमोदन उपरांत जारी किया जा रहा है।

निदेशक (जन स्वास्थ्य)
चिकित्सा एवं स्वास्थ्य सेवायें
राजस्थान, जयपुर

प्रतिलिपि:— निम्न को सूचनार्थ एवं आवश्यक कार्यवाही हेतु—
1. निजी सचिव, अतिरिक्त मुख्य सचिव, चिकित्सा एवं स्वास्थ्य विभाग, राजस्थान।
2. निजी सचिव, शासन सचिव, चिकित्सा शिक्षा विभाग राजस्थान।
3. निजी सचिव, शासन सचिव, आयुर्वेद एवं भारतीय चिकित्सा विभाग, जयपुर, राजस्थान।
4. अति.निदेशक (प्रा. स्वा.) चिकित्सा पूर्व स्वास्थ्य सेवायें।
5. अध्यक्ष, एसएमएस अस्पताल, जयपुर, राजस्थान।
6. निदेशक, राष्ट्रीय आयुर्वेद संस्थान, जयपुर, राजस्थान।
7. सक्षम पत्राध्यापी।

निदेशक (जन स्वास्थ्य)
चिकित्सा एवं स्वास्थ्य सेवायें
राजस्थान, जयपुर
विषय— कोविड-19 के संदिग्धों एवं कोरोना पॉज़िटिव रोगियों पर आौषधि परीक्षण/ उपयोगिता की स्वीकृति प्रदान करने बाबत।

उपरोक्त विषयानलगत अनुरोध है राज्यीय आयुर्वेद संस्थान (आयुर्यं मंत्रालय, भारत सरकार का स्वतित्पोषित निकाय) जयपुर द्वारा कोविड-19 के संदिग्धों एवं कोरोना पॉज़िटिव रोगियों पर आौषधि परीक्षण एवं उपयोगिता की स्वीकृति हेतु दो प्रस्ताव इस विभाग को प्रस्तुत किये हैं। उक्त परीक्षण/प्रक्रिया में सम्पन्न व्यक्तियों/मरीजों को समस्त दीर्घकालिक राज्यीय आयुर्वेद संस्थान द्वारा ही आौषधें आपूर्ति की जायेगी। प्रस्ताव में जयपुर स्थित क्वार्टाइन सेंटर्स के 500 नागरिकों तथा कोविड-19 के 200 मरीजों पर आौषधि उपयोगिता की स्वीकृति प्रदान की जानी अपेक्षित है। उपरोक्त प्रस्ताव आयुर्वेद विभाग अनुसंधान एवं शास्त्रीय विवेचना के अनुरुप है।

अतः समस्त उपरोक्त प्रस्तावों की प्रतिलिपि संलग्न कर अनुरोध है कि इनका परीक्षण/अनुमोदन सरकारी सिंह चिकित्सालय जयपुर में गठित Ethics Committee एवं Clinical Trial Screening Committee से करवाने हेतु निर्देश प्रदान करना कहते हैं। उक्त अनुसंधान के आवश्यक सम्बन्धी (Data) का प्रकाशन राज्य सरकार के सहयोग से किया जाएगा, साथ ही सम्पूर्ण आौषधीय, मानव संसाधन, परीक्षण आदि का दायित्व राज्यीय आयुर्वेद संस्थान को रहेगा।

संलग्न— उपरुपक्षानुसार।

(गायत्री राठोड़)

शासन सचिव

अतिरिक्त मुख्य सचिव

चिकित्सा एवं स्वास्थ्य विभाग

अशा. टीप कमांड— P.25(5)आयु./2020 पार्ट

जयपुर, दिनांक— 2 जून, 2020

प्रतिलिपि— निदेशक, राज्यीय आयुर्वेद संस्थान जयपुर को उनके प्रस्ताव COVID/Dir/02/01 Dt. 08-05-2020 के परिपत्र में सूचनार्थ एवं अप्रीम आवश्यक कर्मों की हेतु प्रस्तुत है।

(आर.पी. चतुरवाड़ी)

शासन उप सचिव
No.- COVID/Dir/02/01

Dated: 08.05.2020

To

The Secretary
Department of Ayurveda
Govt. of Rajasthan
Jaipur (Rajasthan)

Subject: Submission of the proposals for the permission for Ayurvedic drug intervention (treatment protocol) in quarantined patients and COVID 19 positive patients.

Respected Madam

Regards and Greetings of the day from National Institute of Ayurveda, Jaipur.

At the outset I am thankful to your good self and the Govt. of Rajasthan for principally allowing Ayurvedic interventions in quarantined and COVID 19 positive patients (vide letter no. M.25(5) AVU/2020 part dated 06.05.2020). This is really a big step of the state Government for the benefit of ailing humanity and its positive effects will go along way.

I along with this letter submitting the Ayurvedic interventional proposals for your reference and request you to please allow us to intervene in both the groups as mentioned above (Quarantined and COVID 19 positive). For both the categories we are having separate intervention proposals.

We further request you to assign us approximately 500 quarantined patients and about 400 COVID 19 positive patients (with no symptoms or mild symptoms or moderate symptoms). We shall give as an add on treatment. The conventional treatment protocol will continue as such. It is also important to mention that in patients with severe symptoms or critically ill patients or patients having co-morbidities will not be given this treatment.

All the interventional drugs will be provided to the patients by NIA free of cost. We shall also monitor the patients at our own when Ayurvedic treatment will start.

Thanks a lot

Prof. Sanjeev Sharma
Director
Proposal for Ayurveda Therapy As Preventive Medicine to the Subjects kept in Quarantine

- Under the primary supervision of Prof. Sanjeev Sharma, Director, NIA, a Team of NIA physicians will Administer the Treatment protocol

- Treatment site: Identified Quarantine Centres
Ayurveda Therapy As Preventive Medicine to the Subjects kept in Quarantine

Background

Coronavirus disease 2019 (COVID-19) is a newly emerging respiratory tract infection caused by a newly evolved coronavirus, SARS-CoV-2, that was first recognized in Wuhan, China, in December 2019.1

SARS-CoV-2 causes a respiratory infection with a highly variable clinical course that is dependent on host and organism factors.2 81% of patients were reported with Mild disease in the initial Wuhan report, manifesting as self-limited respiratory symptoms typical of a viral pneumonia, including fever, cough, dyspnea, sore throat but also, interestingly, anosmia and dysgeusia.3 14% of the cases in the same cohort were observed to progress to Severe disease -florid pneumonia which may progress to acute respiratory distress syndrome (ARDS) along with cardiogenic or distributive shock.4

Subsequent studies, conducted in other geographic locations and patient populations, showed a different distribution of clinical severity among patients. Mortality rates associated with severe COVID-19 are high (8-25%), despite aggressive supportive measures including mechanical ventilation.5 Individuals most vulnerable to developing severe and critical disease include those of advanced age or with significant comorbid conditions, such as cardiovascular disease, chronic obstructive pulmonary disease, and hypertension.

The acute shortage of ventilators worldwide for treating COVID-19 patients has compounded the problem of the lack of any preventive or curative medicine.6 Therefore it is the need of the hour to search for any viable alternative as preventive measures. WHO to concurs that "traditional remedies may provide comfort and alleviate symptoms of COVID-19".7

The analysis of epidemiological data of COVID-19 till date with an Ayurvedic perspective leads us to the following major Samprapti tenets:

- Janapadodhwamsa
- Pranavaha Srotodushti
- Raktavaha Srotodushti
- Pradhanik karana- SARS-CoV-2
- Vatolvana Sannipatik Jwara
- Rajayaksha

With these justifications the present treatment module, for the frontline warriors and / or those contacts and subjects kept in Quarantine, is being proposed:
• **Interventions** (Ayurvedic drug combination):
  1. **Samshamani Vati** 250 mg, 2 Tabs, twice a day,
  2. **Chyawanprash Avaleha** 20 Gms twice a day and
  3. **Gojihvadi Kwatha**, 30 ml, twice a day

• **Ayurvedic drug combination**
  1. **Samshamani Vati**:

     (Reference: Siddha Yoga Sangraha, Jwara Adhikara, AFI Vol. II.)

     Samshamani Vati is another name for Guduchi Ghana Vati. Guduchi Ghana is one of the unique Ayurved classical preparation which is prepared from aqueous of extract of Guduchi (Tinospora cordifolia Miers.) stem. It is one of the frequently used drugs treat Madhumeha, Pandu, Kamala, Amlapitta, Grahani, Kushta, Jima Jwara and Visamjwara, Trishna, Shool, Yakritavikara, etc.

     **Guduchi (Tinospora cordifolia (Willd.) Miers)** (family Menispermaceae) is an important medicinal plant. It is widely distributed in India, extending from the Himalayas down to the southern part of peninsular India. It is categorized as “Rasayana” and used for its anti-inflammatory, immunomodulatory, properties etc. The whole plant is used medicinally; however, the stem is approved for use in medicine as listed by the Ayurvedic Pharmacopoeia of India. This is due to higher alkaloid content in the stems than in the leaves. **Guduchi Ghana** (concentrated form of decoction) is the secondary **Kalpana** (formulation) derived from the primary **Kalpana**, i.e. **Kwatha** (decoction). The freshly collected stem will be cut into small pieces; soaked in four times of water and made decoction of it. The decoction will be reheated until it becomes semisolid and dried in the oven at 55°C. This Ghana will be rolled into pills of 250 mg each.

**Contents: Guduchi Ghana**

**Dosage:** 250 mg, 2 Tabs, twice a day

2. **Chyavanaprasavaleha 13**

    विल्वोप्रिसम्भ्य: श्वेताक: काश्मर्यः पाटलिपिल:|62
    ................. द्वयं च्यवनप्राशः परमुको रसायनः|||69||
3. Gojihvadi Kwatha

Ingredients of Gojihvadi Kwatha

An equal amount of:
- Gojihva Onosma bracteatum Whole Plant,
- Yastimadhu Glycerhiza glabra Root,
- Sauf Foniculum vulgare Fruit,
- Draksha Vitis vinefera Dry fruit,
- Anjir Ficus carica Dry Fruit,
- Unnav Zizyphus sativa Fruit,
- Vasa Adhatoda vasica Whole Plant,
- Juja Hyssopus officinalis Whole Plant
- Sapistan Cordia latifolia Fruit,
- Khubkalam Sisymbrium irio Seed,
- Gulavanaphsa Viola odorata Flower,
- Hansraj Adiantum lanulatum Whole Plant,
- Atasi Linum usitatissimum Seed,
- Khatmi Althoea officinalis Seed,
- Kantakari Solanum surattance Root and
- Marich Black pepper in half amount

Dosage: 30 ml of Kwatha (liquid/decoction form) diluted with an equal amount of water

twice daily

SOP:
- Subjects' Vitals will be assessed on day 0.
- Subjects will be educated and informed of the common measures to be taken as per the guidelines of Central/State/local health authorities to prevent the spread of the disease.
- AYD will be given to the Subjects and they will be advised to take it as per the dosage schedule. Record will be kept of their daily health condition.
Data collection:
- Epidemiological data with Ayurvedic perspective will be collected.
- Information on socio-demographic, clinical (Allopathic and Ayurvedic) and outcomes will be collected.

Data analysis:
- Descriptive analysis of baseline characteristics including clinical profile
- Outcomes will be assessed and analyzed with reference to baseline variables using SPSS statistical Package

<table>
<thead>
<tr>
<th>Activity</th>
<th>Baseline (Day 0)</th>
<th>End of First week (Day 7)</th>
<th>Completion of Treatment Schedule or Day 14 or 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic Data and History, Prakruti</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Physical and systemic Examinations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Assessment of health related parameters</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Dispensing</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Global assessment of safety and efficacy</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Assessment of vitals, safety and ADR/Adverse Events monitoring</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Compliance</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Subjects protection

- Guduchi is recommended by the Ministry of AYUSH in clinical trials of COVID-194
- Chyawanprasha and Gojihvadi Kwatha are approved by the Institutional Human Ethics Committee of NIA for COVID-19.
- The Treatment SOP details will be explained to the patients & voluntary, written informed consent will be taken.

Expected benefits

- The Ayurvedic Drugs may prove beneficial to the patients
- The Treatment protocol will go a long way in generating evidence of the efficacy of Ayurvedic interventions in Prevention of COVID-19.
- The report will be shared with all the stakeholders
- The evidence so generated will provide a foundation for further trials as well as help in framing treatment guidelines and protocols.

References


6 https://www.who.int/news-room/q-a-detail/q-a-coronaviruses#:~:text=protect (Retrieved 14th April 2020)

7 Ibid.


Proposal for Integrated Ayurveda Therapy As Adjuvant To Conventional Medicine In COVID-19 Patients

- Under the primary supervision of Prof. Sanjeev Sharma, Director, NIA, a Team of NIA physicians will Administer the Treatment protocol

- Treatment site: Identified COVID-19 Isolation Centre


Integrated Ayurveda Therapy As Adjuvant To Conventional Medicine In COVID-19 Patients

Background

Coronavirus disease 2019 (COVID-19) is a newly emerging respiratory tract infection caused by a newly evolved coronavirus, SARS-CoV-2, that was first recognized in Wuhan, China, in December 2019.1

SARS-CoV-2 causes a respiratory infection with a highly variable clinical course that is dependent on host and organism factors.2 81% of patients were reported with Mild disease in the initial Wuhan report, manifesting as self-limited respiratory symptoms typical of a viral pneumonia, including fever, cough, dyspnea, sore throat but also, interestingly, anosmia and dysgeusia.3 14% of the cases in the same cohort were observed to progress to Severe disease florid pneumonia which may progress to acute respiratory distress syndrome (ARDS) along with cardiogenic or distributive shock.4

Subsequent studies, conducted in other geographic locations and patient populations, showed a different distribution of clinical severity among patients. Mortality rates associated with severe COVID-19 are high (8-25%), despite aggressive supportive measures including mechanical ventilation.5 Individuals most vulnerable to developing severe and critical disease include those of advanced age or with significant comorbid conditions, such as cardiovascular disease, chronic obstructive pulmonary disease, and hypertension.

The acute shortage of ventilators worldwide for treating COVID-19 patients has compounded the problem of the lack of any preventive or curative medicine.6 Therefore it is the need of the hour to search for any viable alternative. WHO to concurs that “traditional remedies may provide comfort and alleviate symptoms of COVID-19”.7

The analysis of epidemiological data of COVID-19 till date with an Ayurvedic perspective leads us to the following major Samprapti tenets:

- Janapadodhwamsa
- Pranavaha Srotodushti
- Raktavaha Srotodushti
- Pradhanik karana- SARS-CoV-2
- Vatolvana Sannipatik Jwara
- Rajayaksha

With these justifications the present treatment module is being proposed:
• **Interventions** (Ayurvedic drug combination as adjuvant + Standard Allopathic treatment):

1. **Shati-Pushkarmuladi Vati** 250 mg, 2 Tabs, twice a day,
2. **Chyawanprash Avalahe** 20 Gms twice a day and
3. **Gojihvadi Kwatha**, 30 ml, twice a day

• **Ayurvedic drug combination**

1. **Shati-Pushkarmuladi Vati**: SPV is Shati-Pushkarmuladi Ghana vati adapted from Shati-Pushkarmuladi Churna and is indicated in the Sannipata jvara with manifestations similar to COVID-19:

\[\text{शती पुकर्मुल व त्वा प्रणी शुद्धी दुरालभा} \quad \text{जुद्धी नागरं पाठा किरान सुनसुनद्रिनि} \quad \text{एष शतियाँधिको वरस: सतिसपातज्वाराप्रु:} \quad \text{कासहंग्रह्यांश्वसतिशालंध्रु सहस्यते} \quad \text{(प.च.3.211-212)}\]

---

**Contents:**

- Precautionary measures:
- Management
- Management in a hospice or nursing home or in a ward, case is discussed.

---

**Dosage:** 250 mg, 2 Tabs, twice a day
2. Chyavanaprashavaleha 8

Dosage: 20 gms twice a day

3. Gojihvadi Kwatha

Ingredients of Gojihvadi Kwatha
An equal amount of:
- Gojihva Onosma bracteatum Whole Plant,
- Yastimadhu Glycrrhiza glabra Root,
- Saunf Foniculum vulgare Fruit,
- Draksha Vitis vinefera Dry fruit,
- Anjir Ficus carica Dry Fruit,
- Unnav Zizyphus sativa Fruit,
- Vasa Adhatoda vasica Whole Plant,
- Jufa Hyssopus officinalis Whole Plant
- Sapistan Cordia latifolia Fruit,
- Khubkalam Sisymbrium irio Seed,
- Gulavanaphsa Viola odorata Flower,
- Hansraj Adiantum lanulatum Whole Plant,
- Atasi Linum usitatissimum Seed,
- Khatmi Althoea officinalis Seed,
- Kantakari Solanum surattance Root and
- Marich Black pepper in half amount

Dosage: 30 ml of Kwatha (liquid/decoction form) diluted with an equal amount of water twice daily

SOP:
• Subjects' Vitals will be assessed on day 0.
• Subjects will be educated and informed of the common measures to be taken as per the guidelines of Central/State/local health authorities to prevent the spread of the disease.
• AYD will be given to the patients and they will be advised to take it as per the dosage schedule. Record will be kept of their daily health condition.
• Subjects who turn negative for SARS CoV-2 will be asked to discontinue taking AYD.

Data collection:
• Epidemiological data with Ayurvedic perspective will be collected.
• Information on socio-demographic, clinical (Allopathic and Ayurvedic) and outcomes will be collected.

Data analysis:
• Descriptive analysis of baseline characteristics including clinical profile
• Outcomes will be assessed and analyzed with reference to baseline variables using SPSS statistical Package

<table>
<thead>
<tr>
<th>Activity</th>
<th>Baseline (Day 0)</th>
<th>End of First week (Day 7)</th>
<th>Completion of Treatment Schedule or Day 14 or 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic Data and History, Prakruti</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Physical and systemic Examinations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Assessment of health related parameters and confirmation of Covid-19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Dispensing</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Global assessment of safety and efficacy</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Assessment of vitals, safety and ADR/Adverse Events monitoring</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Compliance</td>
<td></td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>
Patients protection

- Protocol is approved by the Institutional Human Ethics Committee of NIA.
- The Treatment SOP details will be explained to the patients & voluntary, written informed consent will be taken.

Expected benefits

- The Ayurvedic Drugs may prove beneficial to the patients
- The Treatment protocol will go a long way in generating evidence of the efficacy of Ayurvedic interventions in COVID-19.
- The report will be shared with all the stakeholders
- The evidence so generated will provide a foundation for further trials as well as help in framing treatment guidelines and protocols.

References


7. Ibid.

Health and AYUSH Ministers formally launch inter-disciplinary studies involving AYUSH interventions for COVID 19 situation

Posted On: 07 MAY 2020 2:51PM by PIB Delhi

Health Minister Sh. Harsh Vardhan and Minister of State for AYUSH Sh. Shripad Yesso Naik jointly launched clinical research studies on Ayurveda interventions as an add-on to standard care to COVID 19 situation and Ayush Sanjivani application today at New Delhi. AYUSH Minister was participating in the programme through Video Conferencing from Goa.

Speaking on the occasion Dr Harsh Vardhan informed that through a graded, pre-emptive and pro-active approach, Government of India is taking several steps for prevention, containment and management of COVID-19. These are being regularly reviewed and monitored at the highest level.

Dr Harsh Vardhan said, “India has a history of traditional medicine since long and being the pioneer in the field of Ayurveda, the Ministry of AYUSH is working to address the COVID 19 pandemic problem in the country through clinical studies (prophylactic and add-on interventions) of AYUSH systems.

The Union Health Minister said that the Ayush Sanjivani mobile app developed by Ministry of AYUSH will be useful to generate data on acceptance and usage of AYUSH advocacies and measures among the population and its impact in prevention of COVID 19.

On this occasion Shri Shripad Naik said that the Ministry of AYUSH has taken initiatives to address the COVID 19 pandemic problem in the country through clinical studies (prophylactic and add-on interventions) of AYUSH systems and also studying the impact of AYUSH based prophylactic interventions in high risk population. The ministry is also studying the impact of AYUSH advocacies and AYUSH measures for prevention of COVID 19 among the population.

Shri Naik further informed that the Ministry of AYUSH has undertaken four clinical and population based studies to find a better solution to the problem and to assess the role of AYUSH for prevention of the disease.

Speaking on this occasion Secretary, Ministry of AYUSH Vaidya Rajesh Kotech informed that the Ministry has setup an Interdisciplinary Ayush R&D Task Force with a group of experts under the chairmanship of Dr Bhushan Patvardhan, Vice Chairman,
University Grant Commission (UGC) to formulate and develop strategies for this initiative.

The Joint Secretary, AYUSH Shri P.N. Ranjit Kumar gave presentation and explained in detail about three AYUSH based studies related to COVID-19. He also informed the gathering about the Sanjivni App and explained the benefit of Ayurveda. While talking about the three AYUSH based studies, he gave full details about development of the idea, crowd sourcing, making of the task force, alliance of various institutes like SGPGI, AIIMS, ICMR, CSIR & bringing the idea to reality.

The following studies were formally launched in the programme:

1. **Clinical research studies on Ayurveda interventions as prophylaxis and as an add-on to standard care to COVID 19**: Collaborative clinical studies as a joint initiative of Ministry of AYUSH, Ministry of Health and Family Welfare (MoHFW) and the Ministry of Science & Technology through Council of Scientific & Industrial Research (CSIR) with technical support of ICMR.

   The **Interdisciplinary Ayush R&D Task Force** has formulated and designed clinical research protocols for prophylactic studies and add-on interventions in COVID-19 positive cases through thorough review and consultative process of experts of high repute from different organisations across the country for studying four different interventions viz. Ashwagandha, Yashtimadhu, Guduchi + Pippali and a poly herbal formulation (AYUSH-64)

   a. Ashwagandha for the Prophylaxes Against SARS-COV-2 in subjects with increased risk during the COVID 19 Pandemic: A comparison with Hydroxychloroquine in the health care providers and

   b. Effectiveness of Ayurveda Formulation as an adjunct to ‘Standard of Care’ for the Treatment of Mild to Moderate COVID-19: A Randomized, Open Label, Parallel Efficacy, Active Control, Multi-Centre Exploratory Drug Trial.

2. **Population based interventional studies on impact of AYUSH based prophylactic interventions**: The ministry of AYUSH is initiating population based studies to study the impact of Ayurvedic Interventions in prevention of COVID-19 infection in high risk population. The core objectives comprise of, assessment of preventive potential of AYUSH interventions for COVID 19 and also to assess the improvement in Quality of Life in high risk population. The study will be carried out through four Research Councils under Ministry of AYUSH and National Institutes in 25 states across the country and several State Governments covering approximately 5 lakhs population.
The outcome of the study would certainly pave a new horizon in understanding the preventive potential of AYUSH interventions during pandemics like COVID 19 through scientific evidence.

3. **Ayush Sanjivani application based study for impact assessment of acceptance and usage of AYUSH advisories in its role in prevention of COVID 19:** The Ministry of AYUSH has developed Ayush Sanjivani mobile app, for generating data of large population with a target of 5 million people. The core expected outcomes includes to generate data on acceptance and usage of AYUSH advocacies and measures among the population and its impact in prevention of COVID 19.

***

RJ/SK

(Release ID: 1621769) Visitor Counter : 449

Read this release in: Marathi, Hindi, Tamil, Telugu, Malayalam